IP Library Granted Patent US 10,202,457
Granted Patent B2
US 10,202,457 · App. 15/245,853 · Granted Feb 12, 2019

Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke

Inventors: Nelson Ruiz-Opazo (Westwood, MA); Victoria L. M. Herrera (Westwood, MA); Francis Joseph Carr (Balmedie, GB)
Assignee: TRUSTEES OF BOSTON UNIVERSITY
C07K16/2863A61K2039/505C07K2317/21C07K2317/24C07K2317/34C07K2317/52C07K2317/53C07K2317/56C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,202,457
App. No.
15/245,853
Granted
Feb 12, 2019
Kind
B2
Abstract

Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments.

Claims (8)

1. An isolated antibody or antigen-binding fragment thereof capable of binding to DEspR (dual endothelin-1/VEGF signal peptide receptor) of SEQ ID NO: 3 comprising heavy and light chain sequences comprising complementarity determining regions (CDRs) of a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 14; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 15; a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 16; a light chain CDR1 having the amino acid sequence of SEQ ID NO: 28; a light chain CDR2 having the amino acid sequence of SEQ ID NO: 29; and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 30.

2. The isolated antibody or antigen-binding fragment thereof of claim 1 , that is an antibody, wherein the antibody is a chimeric, humanized, or composite human antibody or dual antibody.

3. The isolated antibody or antigen-binding fragment thereof of claim 1 , that is an antigen-binding fragment, wherein the antigen-binding fragment is a Fab fragment, a Fab′ fragment, a Fd fragment, a Fd′ fragment, a Fv fragment, a dAb fragment, a F(ab′)2 fragment, a single chain fragment, a diabody, or a linear antibody.

4. An isolated antibody or antigen-binding fragment thereof comprising a humanized heavy chain IgG4 amino acid sequence of SEQ ID NO: 63 and a humanized kappa light chain amino acid sequence of SEQ ID NO: 65.

5. The isolated antibody or antigen-binding fragment thereof of claim 1 , that specifically binds to an epitope of DEspR (dual endothelin-1/VEGF signal peptide receptor) of SEQ ID NO: 1 or SEQ ID NO: 2.

6. The isolated antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody further comprises a conjugate.

7. The isolated antibody or antigen-binding fragment thereof of claim 3 , wherein the antigen-binding fragment further comprises a conjugate.

8. The isolated antibody or antigen-binding fragment thereof of claim 4 , wherein the antibody further comprises a conjugate.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2019
From: CARR, FRANCIS JOSEPH
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 048954/0164 →
CONFIRMATORY LICENSE Recorded Jan 31, 2019
From: BOSTON UNIVERSITY MEDICAL CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048199/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2016
From: RUIZ-OPAZO, NELSON; HERRERA, VICTORIA L.M.
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 040212/0019 →
Continuity (2)
Provisional Application 62208937 · Aug 24, 2015
Related Publication 20170058036A1 · Mar 2, 2017